SNP318
Phase 2Small molecule
SNP318 is one of 47 small molecule programs targeting Efficacy. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Tivicay
GSKPhase 3
Rogaine
PfizerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SNP318. EMBL-EBI & Wellcome Sanger Institute.
- [4]